ArticleTranslational oncology2026
Dissecting immunosuppressive microenvironment in chemotherapy-resistant colorectal cancer through single-cell transcriptomic analysis.
Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Gut microbiome-mediated primary and acquired resistance to immune checkpoint inhibitors in MSI-H/dMMR colorectal cancer: mechanisms, biomarkers, and therapeutic implications-a narrative review.Frontiers in cellular and infection microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundColorectal cancer (CRC) remains a leading cause of cancer-related mortality, with chemotherapy resistance representing a critical barrier to effective treatment. The tumor microenvironment (TME) plays a pivotal role in mediating resistance through complex immunosuppressive mechanisms that remain incompletely understood at cellular resolution.
methodsWe performed comprehensive single-cell RNA sequencing analysis on 13,380 cells from chemotherapy-sensitive and resistant CRC specimens. Following rigorous quality control and dimensional reduction, we conducted unsupervised clustering, cell type annotation, differential expression analysis, functional enrichment assessment, trajectory inference, and cell-cell interaction network reconstruction. In vitro validation was performed using chemotherapy-resistant cell lines (HCT116-OxR and SW480-5FUR) with quantitative RT-PCR and ELISA assays.
resultsSingle-cell analysis revealed profound TME remodeling in resistant tumors characterized by: (1) significant compositional shifts with reduced cytotoxic T cell and NK cell populations and increased regulatory T cells and M2-polarized macrophages; (2) systematic suppression of T cell activation pathways (normalized enrichment score = -2.8, FDR < 0.001) with concurrent upregulation of immunosuppressive programs including hypoxia response, angiogenesis, and metabolic adaptation; (3) enhanced inhibitory cell-cell communication networks featuring elevated PD-L1/PD-1, CTLA-4, TGF-β, and IL-10 signaling; (4) progressive T cell trajectory transitions from cytotoxic effector to exhausted phenotypes; (5) coordinated upregulation of immune checkpoint molecules (PD-L1, TIM-3, LAG-3), inhibitory cytokines (TGF-β1, IL-10), and metabolic enzymes (IDO1, ARG1). In vitro validation confirmed that resistant cell lines exhibited 2.3-5.1-fold transcriptional upregulation and significantly enhanced secretion of immunosuppressive factors (PD-L1, TGF-β1, IDO1, IL-10; all p < 0.001).
conclusionsThis comprehensive single-cell atlas reveals the multi-dimensional immunosuppressive landscape of chemotherapy-resistant CRC, identifying coordinated cellular, molecular, and spatial mechanisms driving immune evasion. Our findings provide candidate biomarkers for predicting treatment resistance and highlight therapeutic vulnerabilities for developing immunotherapy-based combination strategies to overcome chemotherapy resistance in CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.